Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 83,820 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: therapy Clear all
Completed Phase 1 Interventional Results available

Single Dose Partial Breast Radiotherapy

NCT00944528
View directory record Official record
Conditions
Breast Cancer
Interventions
Radiosurgery
Radiation
Lead sponsor
Duke University
Other
Eligibility
55 Years to 80 Years · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 27, 2023 · Synced Oct 20, 2026, 5:30 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Uncovering Neural and Immune Mechanisms of Chronic Pain in Post Treatment Lyme Syndrome

NCT02687165
View directory record Official record
Conditions
Post Treatment Lyme Syndrome (PTLS), Chronic Pain
Interventions
Milnacipran and D-cycloserine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Oct 20, 2026, 5:30 PM EDT
Completed Phase 2 Interventional

A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide

NCT04669665
View directory record Official record
Conditions
Depressive Disorder, Major, Suicidal
Interventions
SLS-002, Placebo, Standard of care, Intranasal device
Drug · Other · Device
Lead sponsor
Seelos Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
21
States / cities
Orange, California • Panorama City, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 20, 2026, 5:30 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis

NCT02295865
View directory record Official record
Conditions
Psoriasis
Interventions
JNJ-38518168 60 mg, JNJ-38518168 30 mg, JNJ-38518168 3 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Los Angeles, California • Santa Monica, California • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2017 · Synced Oct 20, 2026, 5:30 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

NCT03412565
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Melphalan, Prednisone, Carfilzomib
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
16
States / cities
Southington, Connecticut • Jacksonville, Florida • Orlando, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 20, 2026, 5:30 PM EDT
Completed Not applicable Interventional

Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During an Outpatient Palliative Care Visit

NCT02957565
View directory record Official record
Conditions
Malignant Neoplasms of Independent (Primary) Multiple Sites, Advanced Cancer
Interventions
Baseline Questionnaires, Videos, Assessment Questionnaires
Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2020 · Synced Oct 20, 2026, 5:30 PM EDT
Completed Not applicable Interventional

Addressing Under-treatment and Health Equity in AS and MR Using an Integrated EHR Platform

NCT06099665
View directory record Official record
Conditions
Aortic Valve Stenosis, Mitral Regurgitation
Interventions
Automated alert
Behavioral
Lead sponsor
Tempus AI
Industry
Eligibility
18 Years and older
Enrollment
2,118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
6
States / cities
Kansas City, Missouri • Columbus, Ohio • Lima, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 20, 2026, 5:30 PM EDT
Completed Phase 2 Interventional Results available

Platelet-Rich Plasma Therapy for Patellar Tendinopathy

NCT03136965
View directory record Official record
Conditions
Patellar Tendinitis
Interventions
PRP, Dry Needling, Dry Needling - Sham
Biological · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 39 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 20, 2026, 5:30 PM EDT
Completed Phase 3 Interventional Results available

Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months

NCT04516967
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
Avatrombopag, Placebo
Drug
Lead sponsor
Sobi, Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
21
States / cities
Phoenix, Arizona • Long Beach, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 20, 2026, 5:30 PM EDT
Terminated Phase 1 Interventional

Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

NCT00003567
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
filgrastim, sargramostim, therapeutic autologous lymphocytes, O6-benzylguanine, carmustine, temozolomide, in vitro-treated peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2010 · Synced Oct 20, 2026, 5:30 PM EDT
Completed Phase 2 Interventional Results available

Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease

NCT01713400
View directory record Official record
Conditions
Graft vs. Host Disease
Interventions
Ustekinumab, Placebo, Tacrolimus (TAC), Sirolimus
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 20, 2026, 5:30 PM EDT
Not yet recruiting Not applicable Interventional

EMBRACE Study: Enduring Migraine Benefit From Responsive Artery Coil Embolization

NCT07313800
View directory record Official record
Conditions
Migraine Disorders, Refractory Migraine, Chronic Migraine
Interventions
TEMMA Endovascular Treatment
Device
Lead sponsor
Cortex Neurovascular
Industry
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2028 – 2032
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 20, 2026, 5:30 PM EDT
Completed Phase 4 Interventional

Paroxetine and Interpersonal Psychotherapy for Maintaining Health and Well-being in Elderly Individuals With Depression

NCT00178100
View directory record Official record
Conditions
Unipolar Depression
Interventions
Interpersonal Psychotherapy, paroxetine
Behavioral · Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
69 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 2, 2013 · Synced Oct 20, 2026, 5:30 PM EDT
Completed No phase listed Observational

Longitudinal Study of Multiple Symptoms in Advanced Lung Cancer

NCT00422500
View directory record Official record
Conditions
Lung Cancer
Interventions
Questionnaire, Telephone Interactive System, Blood Samples
Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
4
States / cities
Miami, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2012 · Synced Oct 20, 2026, 5:30 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)

NCT00790400
View directory record Official record
Conditions
Tuberous Sclerosis Complex (TSC), Lymphangioleiomyomatosis (LAM)
Interventions
Everolimus (RAD001), Everolimus Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
6
States / cities
Birmingham, Alabama • Phoenix, Arizona • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2017 · Synced Oct 20, 2026, 5:30 PM EDT
Completed Not applicable Interventional Results available

Stereotactic Body Radiotherapy for Spine Tumors

NCT01347307
View directory record Official record
Conditions
Spinal Metastases, Vertebral Metastases, Benign Spinal Tumors, Chordoma, Meningioma, Schwannoma, Neurofibroma, Paragangliomas, Arteriovenous Malformations
Interventions
SBRT for Benign Extradural Spine Tumors, SBRT for Vertebral/Paraspinal Metastases
Radiation
Lead sponsor
Mercy Research
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Oct 20, 2026, 5:30 PM EDT
Recruiting Phase 2 Interventional

A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures

NCT07219407
View directory record Official record
Conditions
Focal Epilepsy, Epilepsy, Refractory Focal Epilepsy, Seizure, Focal Seizure, Focal Onset Seizure
Interventions
RAP-219
Drug
Lead sponsor
Rapport Therapeutics Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Boise, Idaho • Rochester, Minnesota • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 20, 2026, 5:30 PM EDT
Completed Phase 2 Interventional Results available

Lexapro and Pramipexole and to Treat Major Depression

NCT00086307
View directory record Official record
Conditions
Major Depression
Interventions
Pramipexole, Escitalopram
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 28, 2013 · Synced Oct 20, 2026, 5:30 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Liposomal Bupivacaine With Dexamethasone for Foot Surgery

NCT06465992
View directory record Official record
Conditions
Foot Surgery, Ankle Surgery, Post Operative Pain, Popliteal Nerve Block
Interventions
Exparel 266 MG Per 20 ML Injection, Bupivacaine Hcl 0.75% Inj, Dexamethasone
Drug
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Oct 20, 2026, 5:30 PM EDT
Completed Phase 2 Interventional

Open-Label Study To Evaluate the Safety and Efficacy of the Renal Assist Device In Patients With Acute Renal Failure

NCT00511407
View directory record Official record
Conditions
Acute Renal Failure
Interventions
Renal tubule assist device
Device
Lead sponsor
RenaMed Biologics
Industry
Eligibility
18 Years to 80 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
13
States / cities
Birmingham, Alabama • Augusta, Georgia • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Oct 20, 2026, 5:30 PM EDT
Not listed Not applicable Interventional

Sleep-directed Hypnosis As A Complement To Cognitive Processing Therapy (CPT) In Treating Posttraumatic Stress Disorder (PTSD)

NCT00725192
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Cognitive Processing Therapy, Hypnosis
Behavioral
Lead sponsor
Center for Trauma Recovery, St Louis
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 7, 2011 · Synced Oct 20, 2026, 5:30 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Ultrasound and EMG Guided Botox Injection for the Treatment of Non-Relaxing Puborectalis Syndrome

NCT01780636
View directory record Official record
Conditions
Non-relaxing Puborectalis Syndrome
Interventions
botulinum toxin
Drug
Lead sponsor
Karen Noblett
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 20, 2026, 5:30 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF

NCT00458536
View directory record Official record
Conditions
Renal Cancer
Interventions
Dendritic Cell Tumor Fusion Vaccine, Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
Biological · Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 20, 2026, 5:30 PM EDT
Completed Phase 3 Interventional Results available

Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment

NCT02873936
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Filgotinib, Placebo to match filgotinib, csDMARDs
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
449 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
55
States / cities
Huntsville, Alabama • Gilbert, Arizona • Covina, California + 52 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 20, 2026, 5:30 PM EDT